AzTrials
AzTrials

Opioid-Related DisordersmABCNCT03891628

Modified ABC: A Home-based Parenting Program for Opioid-dependent Mothers and Their Infants

A study testing Modified Attachment and Biobehavioral Catch-up and Modified Developmental Education for Families in people with Opioid-Related Disorders and Parent-Child Relations, run by University of Delaware at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study will assess the efficacy of the modified Attachment and Biobehavioral Catch-Up Intervention, adapted for use with peripartum mothers receiving medication-assisted treatment for opioid use disorder. Read more about this study

Who is it for?
Ages 18 years and older, women only
What is being tested?
Modified Attachment and Biobehavioral Catch-up and Modified Developmental Education for Families
Could I receive a placebo?
No, everyone receives an active treatment
How many people
65 participants
Where
1 siteUnited States
Study dates
13 Aug 2018to 31 Mar 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • In third trimester of pregnancy or up to one month postpartum
  • Receiving medication-assisted treatment for opioid use disorder

Who cannot join

  • None

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Delaware

    Newark, Delaware, 19716

Other trials in United States

About this study

Official title: Modified Attachment and Biobehavioral Catch-Up for Mothers and Their Infants

This study will assess the efficacy of the modified Attachment and Biobehavioral Catch-Up Intervention, adapted for use with peripartum mothers receiving medication-assisted treatment for opioid use disorder. The investigators expect that mothers who receive the modified Attachment and Biobehavioral Catch-up Intervention will show more nurturing and sensitive parenting and more adaptive physiological regulation than parents who receive a control intervention. The investigators expect that infants whose mothers receive the modified Attachment and Biobehavioral Catch-up will show better outcomes in attachment, behavior, and physiological regulation compared to infants of parents who receive the control intervention.

Read the detailed description

Peripartum mothers will be randomly assigned to receive the modified ABC intervention or the control intervention (modified DEF). Hypotheses relate to parent and child outcomes associated with the intervention.

Hypothesis 1: Compared to mothers who receive the control intervention, mothers who receive the ABC intervention will show more nurturing and sensitive parenting, enhanced neural activity during parenting-relevant tasks, and more normative patterns of DNA methylation, autonomic nervous system activity, and cortisol production.

Hypothesis 2: Compared to infants of mothers who receive the control intervention, infants of mothers who receive the ABC intervention will show more organized and secure attachment patterns, better behavioral regulation during stressors, more advanced social-emotional development, and more normative patterns of DNA methylation, autonomic nervous system activity, and cortisol production.

Hypothesis 3: Enhanced maternal sensitivity will mediate effects of the ABC intervention on improved infant outcomes.

Being tested
Modified Attachment and Biobehavioral Catch-up, Modified Developmental Education for Families
Medical subject headings
Opioid-Related Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Modified Attachment and Biobehavioral Catch-upBehavioural

    Also called mABC

    Intervention targets include enhancing nurturance and following the child's lead, as well as supporting use of kangaroo care, swaddling, and breastfeeding.

  • Modified Developmental Education for FamiliesBehavioural

    Also called mDEF

    Intervention targets include supporting developmental monitoring and parental engagement in activities that promote cognitive and motor development.

Study groups in NCT03891628
Study groupRoleWhat they receive
Modified ABCExperimentalModified Attachment and Biobehavioral Catch-Up (14 session in-home intervention with parents and infants present) and Safe Environment for Every Kid (1 to 2 in-home resource visits)
Receives: Behavioral: Modified Attachment and Biobehavioral Catch-up
Modified DEFActive comparatorModified Developmental Education for Families (14 session in-home intervention with parents and infants present) and Safe Environment for Every Kid (1 to 2 in-home resource visits)
Receives: Behavioral: Modified Developmental Education for Families

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Maternal sensitivity

    Maternal sensitivity will be coded observationally from maternal interactions with an infant simulator pre-programmed to coo and then cry. Mothers will be coded for sensitivity, nurturance, intrusiveness, detachment, and positive regard, on 5 point scales from 1-Not at all characteristic to 5-Highly characteristic. Higher scores on sensitivity, nurturance, and positive regard represent more positive parenting, whereas higher scores on nurturance and detachment represent less positive parenting.

    Measured: Pre-intervention (third trimester of gestation or up to one month postpartum)

  2. Maternal sensitivity

    Maternal sensitivity will be coded observationally from mother-infant play interactions, in which mothers will be given toys and asked to play as they normally would. Mothers will be coded for sensitivity, nurturance, intrusiveness, detachment, and positive regard, on 5 point scales from 1-Not at all characteristic to 5-Highly characteristic. Higher scores on sensitivity, nurturance, and positive regard represent more positive parenting, whereas higher scores on nurturance and detachment represent less positive parenting.

    Measured: Infant age 3 months

  3. Maternal sensitivity

    Maternal sensitivity will be coded observationally from mother-infant play interactions, in which mothers will be given toys and asked to play as they normally would. Mothers will be coded for sensitivity, nurturance, intrusiveness, detachment, and positive regard, on 5 point scales from 1-Not at all characteristic to 5-Highly characteristic. Higher scores on sensitivity, nurturance, and positive regard represent more positive parenting, whereas higher scores on nurturance and detachment represent less positive parenting.

    Measured: Infant age 6 months

  4. Maternal sensitivity

    Maternal sensitivity will be coded observationally from mother-infant play interactions, in which mothers will be given toys and asked to play as they normally would. Mothers will be coded for sensitivity, nurturance, intrusiveness, detachment, and positive regard, on 5 point scales from 1-Not at all characteristic to 5-Highly characteristic. Higher scores on sensitivity, nurturance, and positive regard represent more positive parenting, whereas higher scores on nurturance and detachment represent less positive parenting.

    Measured: Infant age 12 months

  5. Maternal methylation of μ-opioid receptor (OPRM1) gene

    Maternal methylation will be assessed using direct bisulfite sequencing of DNA extracted from saliva.

    Measured: Pre-intervention (third trimester of gestation or up to one month postpartum)

  6. Maternal methylation of μ-opioid receptor (OPRM1) gene

    Maternal methylation will be assessed using direct bisulfite sequencing of DNA extracted from saliva.

    Measured: Infant age 3 months

  7. Maternal methylation of μ-opioid receptor (OPRM1) gene

    Maternal methylation will be assessed using direct bisulfite sequencing of DNA extracted from saliva.

    Measured: Infant age 6 months

  8. Maternal methylation of μ-opioid receptor (OPRM1) gene

    Maternal methylation will be assessed using direct bisulfite sequencing of DNA extracted from saliva.

    Measured: Infant age 12 months

  9. Maternal methylation of oxytocin receptor (OXTR) gene

    Maternal methylation will be assessed using direct bisulfite sequencing of DNA extracted from saliva.

    Measured: Pre-intervention (third trimester of gestation or up to one month postpartum)

  10. Maternal methylation of oxytocin receptor (OXTR) gene

    Maternal methylation will be assessed using direct bisulfite sequencing of DNA extracted from saliva.

    Measured: Infant age 3 months

  11. Maternal methylation of oxytocin receptor (OXTR) gene

    Maternal methylation will be assessed using direct bisulfite sequencing of DNA extracted from saliva.

    Measured: Infant age 6 months

  12. Maternal methylation of oxytocin receptor (OXTR) gene

    Maternal methylation will be assessed using direct bisulfite sequencing of DNA extracted from saliva.

    Measured: Infant age 12 months

  13. Infant methylation of μ-opioid receptor (OPRM1) gene

    Infant methylation will be assessed using direct bisulfite sequencing of DNA extracted from saliva.

    Measured: Infant age 3 months

  14. Infant methylation of μ-opioid receptor (OPRM1) gene

    Infant methylation will be assessed using direct bisulfite sequencing of DNA extracted from saliva.

    Measured: Infant age 6 months

  15. Infant methylation of μ-opioid receptor (OPRM1) gene

    Infant methylation will be assessed using direct bisulfite sequencing of DNA extracted from saliva.

    Measured: Infant age 12 months

  16. Infant methylation of oxytocin receptor (OXTR) gene

    Infant methylation will be assessed using direct bisulfite sequencing of DNA extracted from saliva.

    Measured: Infant age 3 months

  17. Infant methylation of oxytocin receptor (OXTR) gene

    Infant methylation will be assessed using direct bisulfite sequencing of DNA extracted from saliva.

    Measured: Infant age 6 months

  18. Infant methylation of oxytocin receptor (OXTR) gene

    Infant methylation will be assessed using direct bisulfite sequencing of DNA extracted from saliva.

    Measured: Infant age 12 months

  19. Maternal neural activity (EEG) - Own child-other child task

    Maternal event-related potentials will be assessed using electroencephalogram (EEG) while viewing photos of their own infants, familiar infants, and unfamiliar infants.

    Measured: Pre-intervention (third trimester of gestation or up to one month postpartum)

  20. Maternal neural activity (EEG) - Own child-other child task

    Maternal event-related potentials will be assessed using electroencephalogram (EEG) while viewing photos of their own infants, familiar infants, and unfamiliar infants.

    Measured: Infant age 12 months

  21. Maternal neural activity (EEG) - Reward sensitivity task

    Maternal event-related potentials will be assessed using electroencephalogram (EEG) while viewing images from four categories: opioid-related images, baby pictures, positive images, and neutral images.

    Measured: Pre-intervention (third trimester of gestation or up to one month postpartum)

  22. Maternal neural activity (EEG) - Reward sensitivity task

    Maternal event-related potentials will be assessed using electroencephalogram (EEG) while viewing images from four categories: opioid-related images, baby pictures, positive images, and neutral images.

    Measured: Infant age 12 months

  23. Maternal neural activity (EEG) - Child emotion task

    Maternal event-related potentials will be assessed using electroencephalogram (EEG) while viewing images of children crying, laughing, and showing neutral expressions.

    Measured: Pre-intervention (third trimester of gestation or up to one month postpartum)

  24. Maternal neural activity (EEG) - Child emotion task

    Maternal event-related potentials will be assessed using electroencephalogram (EEG) while viewing images of children crying, laughing, and showing neutral expressions.

    Measured: Infant age 12 months

  25. Maternal parasympathetic nervous system activity

    Maternal parasympathetic nervous system activity will be assessed using respiratory sinus arrhythmia.

    Measured: Pre-intervention (third trimester of gestation or up to one month postpartum)

  26. Maternal sympathetic nervous system activity

    Maternal sympathetic nervous system activity will be assessed using pre-ejection period.

    Measured: Pre-intervention (third trimester of gestation or up to one month postpartum)

  27. Maternal parasympathetic nervous system activity

    Maternal parasympathetic nervous system activity will be assessed using respiratory sinus arrhythmia.

    Measured: Infant age 3 months

  28. Maternal sympathetic nervous system activity

    Maternal sympathetic nervous system activity will be assessed using pre-ejection period.

    Measured: Infant age 3 months

  29. Maternal parasympathetic nervous system activity

    Maternal parasympathetic nervous system activity will be assessed using respiratory sinus arrhythmia.

    Measured: Infant age 6 months

  30. Maternal sympathetic nervous system activity

    Maternal sympathetic nervous system activity will be assessed using pre-ejection period.

    Measured: Infant age 6 months

  31. Maternal parasympathetic nervous system activity

    Maternal parasympathetic nervous system activity will be assessed using respiratory sinus arrhythmia.

    Measured: Infant age 12 months

  32. Maternal sympathetic nervous system activity

    Maternal sympathetic nervous system activity will be assessed using pre-ejection period.

    Measured: Infant age 12 months

  33. Infant parasympathetic nervous system activity

    Infant parasympathetic nervous system activity will be assessed using respiratory sinus arrhythmia.

    Measured: Infant age 3 months

  34. Infant sympathetic nervous system activity

    Infant sympathetic nervous system activity will be assessed using pre-ejection period.

    Measured: Infant age 3 months

  35. Infant parasympathetic nervous system activity

    Infant parasympathetic nervous system activity will be assessed using respiratory sinus arrhythmia.

    Measured: Infant age 6 months

  36. Infant sympathetic nervous system activity

    Infant sympathetic nervous system activity will be assessed using pre-ejection period.

    Measured: Infant age 6 months

  37. Infant parasympathetic nervous system activity

    Infant parasympathetic nervous system activity will be assessed using respiratory sinus arrhythmia.

    Measured: Infant age 12 months

  38. Infant sympathetic nervous system activity

    Infant sympathetic nervous system activity will be assessed using pre-ejection period.

    Measured: Infant age 12 months

  39. Maternal diurnal cortisol production

    Maternal diurnal cortisol production will be assessed through salivary cortisol levels collected at wake-time and bed-time.

    Measured: Pre-intervention (third trimester of gestation or up to one month postpartum)

  40. Maternal diurnal cortisol production

    Maternal diurnal cortisol production will be assessed through salivary cortisol levels collected at wake-time and bed-time.

    Measured: Infant age 12 months

  41. Infant diurnal cortisol production

    Infant diurnal cortisol production will be assessed through salivary cortisol levels collected at wake-time and bed-time.

    Measured: Infant age 3 months

  42. Infant diurnal cortisol production

    Infant diurnal cortisol production will be assessed through salivary cortisol levels collected at wake-time and bed-time.

    Measured: Infant age 6 months

  43. Infant diurnal cortisol production

    Infant diurnal cortisol production will be assessed through salivary cortisol levels collected at wake-time and bed-time.

    Measured: Infant age 12 months

  44. Infant behavioral regulation - Still Face Paradigm

    Behavioral coding of emotion reactivity and regulation will be conducted from video recordings of the Still Face Paradigm, a mild social stressor.

    Measured: Infant age 6 months

  45. Infant behavioral regulation - Arm Restraint Task

    Behavioral coding of emotion reactivity and regulation will be conducted from video recordings of the Arm Restraint Task, a mild stressor.

    Measured: Infant age 12 months

  46. Infant attachment

    Infant attachment will be assessed using the Strange Situation.

    Measured: Infant age 12 months

  47. Infant cognitive development

    Infant cognitive development will be assessed through maternal report on the Ages and Stages Questionnaire.

    Measured: Infant age 3 months

  48. Infant motor development

    Infant motor development will be assessed through maternal report on the Ages and Stages Questionnaire.

    Measured: Infant age 3 months

  49. Infant social-emotional development

    Infant social-emotional development will be assessed through maternal report on the Ages and Stages Questionnaire: Social-Emotional.

    Measured: Infant age 3 months

  50. Infant cognitive development

    Infant cognitive development will be assessed through maternal report on the Ages and Stages Questionnaire.

    Measured: Infant age 6 months

  51. Infant motor development

    Infant motor development will be assessed through maternal report on the Ages and Stages Questionnaire.

    Measured: Infant age 6 months

  52. Infant social-emotional development

    Infant social-emotional development will be assessed through maternal report on the Ages and Stages Questionnaire: Social-Emotional.

    Measured: Infant age 6 months

  53. Infant cognitive development

    Infant cognitive development will be assessed through maternal report on the Ages and Stages Questionnaire.

    Measured: Infant age 12 months

  54. Infant motor development

    Infant motor development will be assessed through maternal report on the Ages and Stages Questionnaire.

    Measured: Infant age 12 months

  55. Infant social-emotional development

    Infant social-emotional development will be assessed through maternal report on the Ages and Stages Questionnaire: Social-Emotional.

    Measured: Infant age 12 months

  56. Infant social-emotional problems

    Infant social-emotional problems will be assessed through maternal report on the Brief Infant-Toddler Social Emotional Assessment.

    Measured: Infant age 12 months

  57. Maternal self-efficacy

    Mothers will report on their parenting self-efficacy using the Maternal Self-Efficacy Scale. Mothers will rate their self-efficacy for each of ten items (nine discrete parenting behaviors and one global parenting item) on a 4-point scale from 1-not good at all to 4-very good. Scores are summed to form a total maternal self-efficacy composite (possible range = 10-40), where higher scores indicated more maternal self-efficacy.

    Measured: Pre-intervention (third trimester of gestation or up to one month postpartum)

  58. Maternal self-efficacy

    Mothers will report on their parenting self-efficacy using the Maternal Self-Efficacy Scale. Mothers will rate their self-efficacy for each of ten items (nine discrete parenting behaviors and one global parenting item) on a 4-point scale from 1-not good at all to 4-very good. Scores are summed to form a total maternal self-efficacy composite (possible range = 10-40), where higher scores indicated more maternal self-efficacy.

    Measured: Infant age 12 months

  59. Maternal emotion regulation

    Mothers will report on their emotion regulation using the Difficulties with Emotion Regulation Scale - Short Form (DERS-SF). The DERS-SF consists of 18 items rated on a scale from 1-almost never to 5-almost always. The DERS-SF yields six subscales (strategies, non-acceptance, impulse, goals, awareness, and clarity), each of which range from 3 to 15, and one total score, which ranges from 18 to 90. Higher scores indicate greater emotion dysregulation.

    Measured: Pre-intervention (third trimester of gestation or up to one month postpartum)

  60. Maternal emotion regulation

    Mothers will report on their emotion regulation using the Difficulties with Emotion Regulation Scale - Short Form (DERS-SF). The DERS-SF consists of 18 items rated on a scale from 1-almost never to 5-almost always. The DERS-SF yields six subscales (strategies, non-acceptance, impulse, goals, awareness, and clarity), each of which range from 3 to 15, and one total score, which ranges from 18 to 90. Higher scores indicate greater emotion dysregulation.

    Measured: Infant age 12 months

Secondary outcomes (25)
  1. Maternal substance use - interview

    The Timeline Followback Interview will be used to assess maternal use of opioids, tobacco, alcohol, marijuana, and other substances.

    Measured: Pre-intervention (third trimester of gestation or up to one month postpartum)

  2. Maternal substance use - interview

    The Timeline Followback Interview will be used to assess maternal use of opioids, tobacco, alcohol, marijuana, and other substances.

    Measured: Infant age 6 months

  3. Maternal substance use - interview

    The Timeline Followback Interview will be used to assess maternal use of opioids, tobacco, alcohol, marijuana, and other substances.

    Measured: Infant age 12 months

  4. Maternal substance use - questionnaire

    Mothers will report their history of substance use using the NIDA ASSIST questionnaire.

    Measured: Pre-intervention (third trimester of gestation or up to one month postpartum)

  5. Maternal substance use - questionnaire

    Mothers will report recent substance use using the NIDA Quick Screen questionnaire.

    Measured: Infant age 3 months

  6. Maternal substance use - questionnaire

    Mothers will report recent substance use using the NIDA Quick Screen questionnaire.

    Measured: Infant age 6 months

  7. Maternal substance use - questionnaire

    Mothers will report recent substance use using the NIDA Quick Screen questionnaire.

    Measured: Infant age 12 months

  8. Maternal depressive symptoms

    Maternal depressive symptoms will be self-reported using the Beck Depression Inventory.

    Measured: Pre-intervention (third trimester of gestation or up to one month postpartum)

  9. Maternal depressive symptoms

    Maternal depressive symptoms will be self-reported using the Beck Depression Inventory.

    Measured: Infant age 3 months

  10. Maternal depressive symptoms

    Maternal depressive symptoms will be self-reported using the Beck Depression Inventory.

    Measured: Infant age 6 months

  11. Maternal depressive symptoms

    Maternal depressive symptoms will be self-reported using the Beck Depression Inventory.

    Measured: Infant age 12 months

  12. Infant physical growth

    Infant physical growth will be assessed using weight, length, and head circumference.

    Measured: Infant age 3 months

  13. Infant physical growth

    Infant physical growth will be assessed using weight, length, and head circumference.

    Measured: Infant age 6 months

  14. Infant physical growth

    Infant physical growth will be assessed using weight, length, and head circumference.

    Measured: Infant age 12 months

  15. Maternal experiences during labor and delivery

    Mothers will report on their experiences during labor and delivery using the Birth Satisfaction Scale-Revised questionnaire (BSS-R). This measure consists of ten items rated on a 5-point scale from 1-Strongly Disagree to 5-Strongly Agree. The total score ranges from 10-50, where higher scores represent more birth satisfaction.

    Measured: Infant age 3 months

  16. Home environment

    The home environment will be assessed using the Cognitive Stimulation subscale of the HOME Short Form, a combination of observation (two items) and maternal report (seven items). Observation items are binary (yes/no), and mother-report items are rated on a Likert-type scale and dichotomized. Dichotomous items are summed to form a total score (range 0-9), with higher scores indicating more cognitive stimulation.

    Measured: Infant age 3 months

  17. Maternal reward responsiveness

    Mothers will report their reward responsiveness using the Reward Responsiveness Scale. This is an 8-item scale rated on a 4-point scale from 1-Strong Disagreement to 4-Strong Agreement. The total score ranges from 8 to 32, with higher scores representing greater reward responsiveness.

    Measured: Pre-intervention (third trimester of gestation or up to one month postpartum)

  18. Maternal reward responsiveness

    Mothers will report their reward responsiveness using the Reward Responsiveness Scale. This is an 8-item scale rated on a 4-point scale from 1-Strong Disagreement to 4-Strong Agreement. The total score ranges from 8 to 32, with higher scores representing greater reward responsiveness.

    Measured: Infant age 12 months

  19. Maternal sleep

    Mothers will report on their sleep habits using the Pittsburgh Sleep Quality Index.

    Measured: Pre-intervention (third trimester of gestation or up to one month postpartum)

  20. Maternal sleep

    Mothers will report on their sleep habits using the Pittsburgh Sleep Quality Index.

    Measured: Infant age 3 months

  21. Maternal sleep

    Mothers will report on their sleep habits using the Pittsburgh Sleep Quality Index.

    Measured: Infant age 6 months

  22. Maternal sleep

    Mothers will report on their sleep habits using the Pittsburgh Sleep Quality Index.

    Measured: Infant age 12 months

  23. Infant sleep

    Mothers will report on their infant's sleep habits using the Brief Infant Sleep Questionnaire.

    Measured: Infant age 3 months

  24. Infant sleep

    Mothers will report on their infant's sleep habits using the Brief Infant Sleep Questionnaire.

    Measured: Infant age 6 months

  25. Infant sleep

    Mothers will report on their infant's sleep habits using the Brief Infant Sleep Questionnaire.

    Measured: Infant age 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Mar 2019
  2. Study start13 Aug 2018
  3. Primary completion31 Mar 2021
  4. Study completion31 Mar 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
65 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03891628
Sponsor's protocol ID
PSYC412125
Acronym
mABC
Status last verified
Aug 2021
First submitted
21 Feb 2019
Last updated
1 Sep 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Tabachnick AR, Eiden RD, Labella MH, Dozier M. Effects of an attachment-based intervention on autonomic regulation among opioid-exposed infants. Dev Psychobiol. 2022 Sep;64(6):e22286. doi: 10.1002/dev.22286.

    PubMed 35748625

Questions about this trial

What is this clinical trial studying?

A study testing Modified Attachment and Biobehavioral Catch-up and Modified Developmental Education for Families in people with Opioid-Related Disorders and Parent-Child Relations, run by University of Delaware at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 1 Sep 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Maternal sensitivity (time frame: Pre-intervention (third trimester of gestation or up to one month postpartum)). The study lists 60 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03891628, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Sep 2021; AzTrials last refreshed its copy on 26 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in